Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

(2022) Ashley H. Shoemaker et al.   INTERNATIONAL JOURNAL OF OBESITY

MRI measures of hypothalamic injury are associated with GLP ‐1 receptor agonist treatment response in people with hypothalamic obesity

(2021) Francisco A. Perez et al.   DIABETES OBESITY & METABOLISM

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

(2021) Jamy Ard et al.   ADVANCES IN THERAPY

Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome

(2021) Nathalie Kayadjanian et al.   PLoS One

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

(2020) Aaron S. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity

(2020) Christian L. Roth et al.   DIABETES OBESITY & METABOLISM

Assessment and management of hypoglycemia in children and adolescents with diabetes

(2018) Mary B Abraham et al.   PEDIATRIC DIABETES

Obesity management in Prader–Willi syndrome: current perspectives

(2018) Antonino Crinò et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

(2017) Carel W le Roux et al.   LANCET

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

Prader–Willi syndrome: From genetics to behaviour, with special focus on appetite treatments

(2015) Joanne L. Griggs et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoglycemia in Prader-Willi syndrome

(2014) Rena A. Harrington et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Use of GLP-1 Receptor Agonists in Prader-Willi Syndrome: Report of Six Cases

(2014) Danilo Fintini et al.   DIABETES CARE

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

(2014) Anna Secher et al.   JOURNAL OF CLINICAL INVESTIGATION

GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases

(2013) Flavius Zoicas et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of a Single Dose of Exenatide on Appetite, Gut Hormones, and Glucose Homeostasis in Adults with Prader-Willi Syndrome

(2011) Lisa Sze et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Health Supervision for Children With Prader-Willi Syndrome

(2010)   PEDIATRICS